Dennis Ding
Stock Analyst at Jefferies
(0)
# 4851
Out of 5,240 analysts
17
Total ratings
14.29%
Success rate
-27.32%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Inhibikase Therapeut... | Initiates Coverage On: Buy | 8 | 2.82 | 183.69% | 1 | Nov 8, 2024 | |
Assembly Biosciences | Upgrades: Buy | 2 35 | 14.93 | 134.43% | 1 | Sep 20, 2024 | |
Amicus Therapeutics | Initiates Coverage On: Buy | 18 | 9.26 | 94.38% | 1 | Sep 6, 2024 | |
Arbutus Biopharma | Maintains: Strong Buy | 5 7 | 3.29 | 112.77% | 2 | Sep 5, 2024 | |
Recursion Pharmaceut... | Maintains: Hold | 8 6 | 6.59 | -8.95% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 1 | 0.19 | 163.16% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 216 | 4.71 | 4485.99% | 1 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 35 22 | 52.97 | -58.47% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 24 | 24.29 | -1.19% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 30 | n/a | n/a | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 25 | n/a | n/a | 1 | Jan 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 195 52 | n/a | n/a | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 10 | 11.08 | -9.75% | 1 | Oct 26, 2021 |